After 31 weeks of treatment with clozapine, severe agranulocytosis was diagnosed in a 35-year-old male schizophrenic patient. The patient was treated sucessfully with a granulocyte colony-stimulating factor (G-CSF). The leukocyte court was 300/mm(3) on admission. After 10 days treatment with G-CSF, the hematological status normalized. Despite its clinical advantages, the use of clozapine has been limited by a propensity to induce agranulocytosis in 1-2% of the patients who are treated with this compound. In addition to case report, authors reviewed the indications for clozapine treatment and the present knowledge base regarding the incidence, monitoring and management of agranulocytosis. Unfortunately, clozapine-induced agranulocytosis cannot be prevented, so regular blood examination and education for patient and family member are very important and early treatment with G-CSF seems warranted in severe cases of clozapine-induced agranulocytosis.
Adult ; Agranulocytosis* ; Clozapine ; Education ; Granulocyte Colony-Stimulating Factor ; Humans ; Incidence ; Knowledge Bases ; Leukocytes ; Male

This study describes the epidemiological characteristics of coronavirus disease 2019 (COVID-19) based on reported cases from long-term care facilities. As of April 20th, 2020, 3 long-term care facilities in a metropolitan area of South Korea had reported cases of COVID-19. These facilities’ employees were presumed to be the sources of infection. There were 2 nursing hospitals that did not report any additional cases. One nursing home had a total of 25 cases, with an attack rate of 51.4% (95% CI 35.6–67.0), and a fatality rate of 38.9% (95% CI 20.3–61.4) among residents. The results from this study suggest that early detection and maintenance of infection control minimizes the risk of rapid transmission.